.png?width=500&height=150&name=ESTIV%20logo%20(1).png "ESTIV logo (1)")
The European Society of Toxicology In Vitro (ESTIV) Congress is a premier forum for advancing in vitro and in silico toxicology, bringing together scientists from academia, industry, and regulatory organizations to share knowledge, foster collaboration, and explore the future of New Approach Methodologies (NAMs). Under the 2026 theme, "Ensuring Safety, Advancing Science: Bridging to the Future with NAMs," the congress highlights innovative, human-relevant approaches that are transforming toxicology while supporting the reduction of animal testing.
LifeNet Health LifeSciences is proud to showcase how our innovative NAMs can help reduce uncertainty and deliver more predictive insights than traditional approaches alone. Designed to better reflect human biology across discovery and safety assessment, our solutions empower toxicologists to generate data they can trust with greater confidence. From high-quality, prospectively recovered human biospecimens to advanced in vitro models and integrated multi-organ microphysiological systems (MPS), our portfolio supports human-relevant science that strengthens safety evaluation and risk assessment.
High Quality Solutions that Better Represent Human Biology
Cells & Cell Models
- TruVivo® 2D+ Hepatic System
- 3D Thyroid Microtissue Model
- Human Hepatocytes and Liver NPCs
In Vitro Assay Services
- Integrated Multi-organ MPS
- Endocrine Disruption Testing
- DMPK/ADMET Studies
Prospective Biospecimens
- Brain, Skin, Gut, and More
- Healthy and Diseased
- Prospective Samples
Innovative NAMs for Human Risk Assessment
TruVivo® 2D+ Hepatic System
TruVivo is an advanced long-term hepatic system that enables in vitro measurement of thyroxine (T4) glucuronidation in rat and human systems to support mechanistic evaluation of indirect thyroid hormone disruption driven by liver metabolism. By preserving nuclear receptor responsiveness over repeated-dose exposures, TruVivo allows quantification of baseline and induced T4G, helping toxicologists distinguish liver-driven clearance effects and interpret species relevance within mechanistic, weight-of-evidence thyroid risk assessments.
Human 3D Thyroid Microtissue Model
The human 3D thyroid microtissue model is a 96-well, organotypic model built from primary human thyrocytes that enables quantitative measurement of thyroid hormone synthesis and secretion. By directly assessing functional hormone output, this assay identifies chemicals that disrupt thyroid hormone production in a human-relevant system, providing mechanistic insight beyond single-target approaches. Available as both a product and a fully supported assay service, it helps discovery and safety teams confidently evaluate potential thyroid liabilities within modern NAM-based workflows.
.png?width=225&height=225&name=MPS%20graphic%20thumbnail%20(2).png "MPS graphic thumbnail (2)")
Integrated Multi-Organ MPS Platform
Our integrated multi-organ MPS platform provides flexible, human-relevant evaluation of pharmacokinetics and toxicity with greater simplicity and affordability than traditional organ-on-chip systems. Isolated tissues are linked via simulated vascular flow in configurable 2-, 3-, or 4-organ designs, such as intestine–liver–kidney or intestine–liver–thyroid, enabling simultaneous assessment of metabolism, clearance, and organ-specific toxicity. The system supports key PK parameters, PBPK modeling, improved IVIVE, and can be deployed in GLP study designs.
Poster Presentation
3D Spheroid Performance of Rat and Human Hepatocytes Comparing Medium and Microplates
Date & Time: Tuesday, June 30, 2026
Board No. P337
Discover how cryopreserved rat and human hepatocytes form functional 3D spheroids that maintain liver phenotype for 21 days. Using both non-diseased and diseased human donors, spheroids showed sustained albumin and urea production, stable CYP3A4 activity, viable ATP levels, formation of bile canalicular networks, and lipid accumulation consistent with steatosis.